Can a Two-Pronged attack shrink Hard-to-Treat cancers?
Disease control
Terminated
This trial tests whether an experimental drug called XNW5004, which blocks a protein that helps cancer grow, can boost the effects of the immunotherapy pembrolizumab (Keytruda) in people with advanced solid tumors that have stopped responding to standard treatments. The study inc…
Phase: PHASE1, PHASE2 • Sponsor: Evopoint Biosciences Inc. • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC